1. Home
  2. AMCI vs KLRS Comparison

AMCI vs KLRS Comparison

Compare AMCI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Robotics Corporation Common Stock

AMCI

AMC Robotics Corporation Common Stock

N/A

Current Price

$4.89

Market Cap

110.5M

Sector

Finance

ML Signal

N/A

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$4.75

Market Cap

113.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCI
KLRS
Founded
2021
2019
Country
United States
United States
Employees
N/A
20
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.5M
113.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AMCI
KLRS
Price
$4.89
$4.75
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
79.5K
74.5K
Earning Date
04-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$33.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$2.14
52 Week High
$15.75
$11.88

Technical Indicators

Market Signals
Indicator
AMCI
KLRS
Relative Strength Index (RSI) 52.35 53.87
Support Level $4.06 $4.27
Resistance Level $5.74 $4.80
Average True Range (ATR) 0.46 0.33
MACD 0.13 0.06
Stochastic Oscillator 32.76 94.44

Price Performance

Historical Comparison
AMCI
KLRS

About AMCI AMC Robotics Corporation Common Stock

AMC Robotics Corp is a technology solutions company that offers AI-powered smart security and robotics solutions. It currently sells smart hardware products designed for residential and commercial use, including smart cameras, driving recorders, action cameras, and Retina K cameras, which are marketed under the YI brand. AMC Robotics is also engaged in developing additional hardware products and technology capabilities, including IoT-enabled devices, AI-based features, wearable devices, and AI robotics. Using its technological capabilities, the company is developing robotic dogs, robotic arms, and robotic unloading systems, offering smart solutions for the logistics and warehousing sectors. It has two primary operating segments: North America, which generates maximum revenue, and Europe.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: